Abstract 1975P
Background
Patients (pts) with metastatic KIT/PDGFRA wild-type (KPWT) gastrointestinal stromal tumours (GIST) usually do not derive any benefit from upfront treatment with imatinib. Most of the studies reported so far include case reports or small series and treatment patterns widely differed according to the medical teams. More studies are therefore needed to define the optimal management of metastatic KPWT GIST pts. The primary aim of this retrospective study was to assess the outcome of pts with KPWT GIST treated by Tyrosine Kinase Inhibitors (TKI) in our institution.
Methods
We conducted a retrospective study at a single institution, the Centre Léon Bérard (CLB). The national sarcoma database (https://netsarc.sarcomabcb.org/) was searched for pts with a diagnosis of KPWT GIST treated at the CLB. Data were extracted from individual patients’ files. All cases were reviewed by an expert sarcoma pathologist. In the absence of a known neurofibromatosis type 1 (NF1) or SDH-deficiency, whole exome-RNAseq was performed on FFPE material.
Results
In total, 86 pts with metastatic KPWT GIST were identified, with a median age at diagnosis of 55 [10-80], a sex-ratio of 0.9 and a median tumor size of 65 mm [11-260]. The primary tumor was in the stomach for 42 pts (49%) and in the duodenum for 40 (47%). The vast majority were KIT and DOG1 positive by IHC (98 and 92%, respectively). Among the 86 pts, 31 (36%) had a metastatic disease, either synchronous (N=15) or metachronous (N=16). The majority of these cases were NF1-associated GIST (N=13, 42%), 7 were SDH-deficient GIST (23%), one was NTRK-rearranged GIST (RBPMS::NTRK3), one harboured TSC1 variant (T314M) and no significant mutation/fusion was detected in 9 GIST. While none of the 31 pts responded to imatinib, 3/3 pts had a partial response with lenvatinib (all SDH-deficient GIST), 1/3 with pazopanib, 2/20 (10%) with sunitinib and 2/10 (20%) with regorafenib. Interestingly, the highest duration of response PFS was with pazopanib (111 months).
Conclusions
This retrospective series of KPWT GIST is one of the largest with this rare disease. Although there was no response to first line TKI imatinib, some long responders are reported with anti-angiogenic TKI and warrant additional investigation through prospective trials to validate those results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
InfoSarcomes, InterSarc.
Disclosure
M. Brahmi: Financial Interests, Personal, Advisory Board: Bayer, Deciphera; Financial Interests, Personal, Invited Speaker: Amgen. A. Dufresne: Non-Financial Interests, Project Lead, Translational research project: GSK, Adaptimmune; Non-Financial Interests, Project Lead, Translational research program: Bayer. P. Cassier: Financial Interests, Personal, Advisory Board: Merck Serono/EMD, Roche, Amgen, Boehringer ingelheim; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Other, Advisor: Ose Immunotherapeutics; Financial Interests, Institutional, Local PI: AbbVie, Blueprint, Exelixis, GSK, Janssen, Novartis, Roche, Taiho, Loxo/Eli Lilly; Financial Interests, Institutional, Coordinating PI: Amgen; Non-Financial Interests, Institutional, Product Samples: Plexxikon, Novartis, MSD, AstraZeneca, GSK. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, Adaptimmun, Eisai, Sutro, BMS, Adaptimmune, Daiichi Sankyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Principal Investigator: PAOLA1; Non-Financial Interests, Other, President: GINECO. J. Blay: Financial Interests, Personal, Advisory Board: Bayer, Deciphera, GSK, Roche; Financial Interests, Personal, Invited Speaker: PharmaMar; Financial Interests, Institutional, Invited Speaker: MSD, MSD; Financial Interests, Personal, Other, member of the supervisory board: Innate pharma; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bayer, GSK, Novartis, OSE pharma. All other authors have declared no conflicts of interest.
Resources from the same session
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15